Note 1 - Organization and Basis of Presentation (Details Textual) - USD ($) $ in Thousands |
1 Months Ended | 3 Months Ended | 36 Months Ended | |||
|---|---|---|---|---|---|---|
Nov. 25, 2025 |
Apr. 30, 2023 |
Mar. 31, 2026 |
Mar. 31, 2025 |
Mar. 31, 2026 |
Dec. 31, 2025 |
|
| Milestone Payment Receivable | $ 90 | $ 90 | $ 3,724 | |||
| Costs and Expenses | $ 27,314 | $ 34,969 | ||||
| PDE7 [Member] | National Institute on Drug Abuse (“NIDA”) [Member] | ||||||
| Grants Receivable | $ 6,240 | |||||
| Grants Receivable, Period | 3 years | |||||
| Costs and Expenses | $ 2,300 | |||||
| Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | Zaltenibart [Member] | ||||||
| Proceeds from Sale of Productive Assets | $ 240,000 | |||||
| Milestone Benchmark One, If Milestone Achieves | 510,000 | |||||
| Milestone Benchmark Two, If Milestone Achieves | 1,300,000 | |||||
| Milestone Payment Receivable | $ 1,800,000 | |||||